Ron Bentsur

Ron Bentsur is a board member at Stemline Therapeutics and has over 20 years of experience in the pharmaceutical industry. Ron has served as the CEO of three companies: UroGen Pharma, Nuvectis Pharma, and Keryx Biopharmaceuticals. Ron has also held the position of Investor Relations and Chief Financial Officer at Keryx.

Ron has led the clinical development, regulatory approval and commercial infrastructure buildout for the US commercial launch of Jelmyto at UroGen Pharma. Ron also successfully established a worldwide partnership for an earlier-stage program at UroGen. Ron was a member of the Board of Directors of Stemline Therapeutics from 2009 through the approval and launch of Elzonris and the subsequent acquisition of the company by the Menarini Group in June 2020.

At Nuvectis Pharma, Ron served as Chief Executive Officer where they successfully managed all aspects of the company. Under their leadership, Nuvectis Pharma became a leading biopharmaceutical company specializing in the development of innovative treatments for serious diseases.

As CEO of Keryx Biopharmaceuticals, Ron successfully led the company through a period of significant growth. During their tenure, Keryx attained numerous milestones, including the approval and launch of Auryxia, a treatment for iron deficiency anemia, and the approval of Zerenex, a treatment for kidney disease. Under Ron’s leadership,

Ron Bentsur began their educational career by earning a Bachelor of Arts in Economics and Business Administration from The Hebrew University of Jerusalem. Ron then went on to earn a Master of Business Administration from NYU Stern School of Business.